ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 146,91
-0,60%
Dow Jones
39 806,77
-0,49%
DAX
18 721,02
-0,25%
Brent Oil
82,745
-0,94%
Bitcoin
70 976,25
-0,66%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. LAVA Therapeutics NV (LVTX)

  7. LAVA Therapeutics NV (LVTX) Actualités

LVTX

LAVA Therapeutics NV (LVTX)

LAVA Therapeutics NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LVTX
DateHeureSourceTitreSymboleSociété
25/01/202414h07Dow Jones NewsLava Therapeutics Shares Rise as Drug Set for Test With Merck's KeytrudaNASDAQ:LVTXLAVA Therapeutics NV
16/11/202322h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
06/09/202313h11GlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LVTXLAVA Therapeutics NV
22/08/202313h00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
14/08/202313h00GlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual ConferenceNASDAQ:LVTXLAVA Therapeutics NV
15/06/202322h51Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
14/06/202315h00GlobeNewswire Inc.LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayNASDAQ:LVTXLAVA Therapeutics NV
08/06/202313h00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
06/06/202312h02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LVTXLAVA Therapeutics NV
06/06/202300h31Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LVTXLAVA Therapeutics NV
02/06/202301h38Dow Jones NewsStocks to Watch: Lululemon, Lava Therapeutics, Tilly's, OncorusNASDAQ:LVTXLAVA Therapeutics NV
01/06/202322h20GlobeNewswire Inc.LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical DevelopmentNASDAQ:LVTXLAVA Therapeutics NV
01/06/202314h09GlobeNewswire Inc.LAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
30/05/202323h28GlobeNewswire Inc.LAVA Announces Annual Meeting of ShareholdersNASDAQ:LVTXLAVA Therapeutics NV
11/04/202313h00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
09/03/202314h05GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsNASDAQ:LVTXLAVA Therapeutics NV
16/02/202313h00GlobeNewswire Inc.LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
09/02/202313h00GlobeNewswire Inc.LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceNASDAQ:LVTXLAVA Therapeutics NV
06/02/202313h00GlobeNewswire Inc.LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical OfficerNASDAQ:LVTXLAVA Therapeutics NV
23/01/202313h00GlobeNewswire Inc.LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
06/01/202319h07GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of New Directors to the BoardNASDAQ:LVTXLAVA Therapeutics NV
03/01/202313h00GlobeNewswire Inc.LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
23/12/202222h02Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:LVTXLAVA Therapeutics NV
12/12/202212h25TipRanksH.C. Wainwright Keeps Their Buy Rating on LAVA Therapeutics (LVTX)NASDAQ:LVTXLAVA Therapeutics NV
10/12/202216h00GlobeNewswire Inc.LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LVTXLAVA Therapeutics NV
16/11/202222h05GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
03/11/202221h05GlobeNewswire Inc.LAVA Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
03/11/202214h00GlobeNewswire Inc.LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LVTXLAVA Therapeutics NV
01/11/202212h00GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial OfficerNASDAQ:LVTXLAVA Therapeutics NV
07/10/202217h00GlobeNewswire Inc.LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual MeetingNASDAQ:LVTXLAVA Therapeutics NV
 Showing the most relevant articles for your search:NASDAQ:LVTX

Dernières Valeurs Consultées

AMEX
SEB.WD
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés